GrowingWithAK

qsif SIF · SIF · SIF-118

qsif Sector Rotation Long-Short Fund - IDCW Option - Direct Plan

Equity Oriented · Sector Rotation Long-Short Fund · Open Ended Scheme · Direct IDCW

ISIN (Payout): INF966L30290 ISIN (Reinvest): INF966L30282

Declared benchmark
NIFTY 500 Total Return Index (TRI)
Fund managers
Sandeep Tandon (since May 2026), Jignesh Shah (since May 2026), Ankit Pande (since May 2026), Sameer Kate (since May 2026), Sanjeev Sharma (since May 2026)
Launched
27 Apr 2026
Minimum investment
₹10 lakh
Risk level (1 low, 5 high)
Level 3 (was Level 5 at launch)
Expense ratio, as filed with AMFI
Regular: 4.36% Direct: 2.81%
Houses fill this field differently. It may be the base expense ratio only, before GST, brokerage and transaction costs.
Custodian
HDFC Bank Limited
SEBI code
QSIF/O/E/SRLS/25/10/0005/QNTM
Exit load
Exit Load: 3% if redeemed/switched out on or before completion of 30 days from the date of allotment of units No Exit Load is payable if Units are redeemed / switched-out after 30 days from the date of allotment
Investment objective

To achieve long-term capital appreciation by concentrating investments in equity and equity-related instruments of up to four high-potential sectors, while employing limited short exposure through derivatives to capitalize on sector-specific downturns and enhance risk-adjusted returns.

From AMFI's strategy details and the house's Scheme Summary Document, checked 16 Oct 2026. Strategy document (PDF) Summary document (PDF)

1 Month

-2.85%

3 Months

-1.42%

6 Months

—

Since Inception

+1.15%

from 2026-05-18

CAGR (Inception)

—

< 1 yr history

NAV 10.1244 as of 2026-10-21 · 156 days of history

Max Drawdown

-3.50%

Worst peak‑to‑trough fall since inception

Annualised Volatility

7.79%

How bumpy the daily NAV journey is

Based on 156 days of NAV history. Green < 5% MDD / < 12% vol · Amber 5-10% / 12-20% · Red > 10% / > 20%

Since inception, from 107 daily returns. Short histories make these noisy, so treat them as provisional.

Sharpe ratio

-0.39

Return per unit of total risk, above a 6% risk-free rate

Sortino ratio

-0.53

Same, but counting only the falls

Beta vs Nifty 500

0.36

1.0 moves with the index; lower means more hedged

Down capture

26%

Share of the index's falls it took on down days (lower is better)

Up capture

33%

Share of the index's gains it kept on up days

Worst month

-0.87%

Jul 2026

Best month

1.73%

Aug 2026

Positive months

4 of 5

Completed calendar months that gained

Drawdown recovery

Not yet

0 days since the worst low

Below its high

-3.50%

How far today's NAV is under the highest NAV so far

Beta and capture use the Nifty 500 price index, matched on 107 common trading days.

House's portfolio file

Strategy assets

₹62 cr

Net assets in the portfolio file

Equity held

70.3%

14 stocks, top 10 = 62.5%

Futures, net

-12.5%

Short -22.4% · long +10.0%

Net equity exposure

57.8%

Equity held plus futures

How the book is built

Arbitrage: 22% of NAV is stock held against its own short futures.

Outright equity 48.0% Hedged by own futures (arbitrage) 22.3% Debt & money market 6.4% Cash & receivables 23.3%
Stock futures bought: 10.0% Net equity exposure 58%

Each future and option is matched to the stock it is written on, and coverage is measured by contracts against shares held: the file shows options at their premium, which would make a collar over half the book look like well under 1% of it.

Asset mix, % of net assets

  • Equity held +70.3%
  • Cash & TREPS +19.8%
  • Futures -12.5%
  • Money market +6.4%
  • Net receivables +3.6%

Blue bars add to the portfolio, orange bars are short or negative positions.

Top 10 stocks held

Indus Towers LimitedTelecom - Services 9.33%
Zydus Lifesciences LimitedPharmaceuticals & Biotechnology 8.77%
Divi's Laboratories LimitedPharmaceuticals & Biotechnology 7.18%
Bharti Airtel LimitedTelecom - Services 6.78%
Gujarat Themis Biosyn LtdPharmaceuticals & Biotechnology 5.81%
Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology 5.68%
Glenmark Pharmaceuticals LtdPharmaceuticals & Biotechnology 5.61%
Lupin LimitedPharmaceuticals & Biotechnology 5.28%
Biocon LtdPharmaceuticals & Biotechnology 4.89%
Mphasis LtdIT - Software 3.12%

Largest short positions (4 in total)

Bharti Airtel Ltd.Futures -6.76%
Sun Pharmaceutical Industries Ltd.Futures -5.68%
Lupin Ltd.Futures -5.18%
Biocon Ltd.Futures -4.82%

Stocks held, by industry

Pharmaceuticals & Biotechnology 46.2%Telecom - Services 16.1%IT - Software 4.3%Healthcare Services 1.8%Consumable Fuels 1.8%

Net assets by portfolio date: Sep 2026 ₹62 cr · Jul 2026 ₹49 cr

From the house's own portfolio statement; SIFs must publish one at least every alternate month-end. Futures are counted at full contract value, so net equity exposure is equity held plus futures. Options are shown at their premium value, not their market exposure, so they are left out of that figure.

2026-05-18 → 2026-10-21

Compare with
Loading…
Since inceptionReturnMax drawdown

All rebased to ₹100 at the SIF's inception. SIFs are long-short (hedged) and aim for a smaller max drawdown rather than out-running a fully-invested fund/index in a rising market, so weigh the drawdown column alongside return.

Quarter Valued on ₹ crore
Apr-Jun 2026 30 Jun 2026 0.01

What the fund house itself has invested in this strategy, as filed with AMFI each quarter. This is the house's own stake, not the size of the strategy (AUM). AMFI does not publish AUM for individual SIF strategies.

How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.

Year Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year
2026 · · · · · +1.4 -0.9 +1.7 +0.0 -1.8 · · +0.5
Avg · · · · · +1.4 -0.9 +1.7 +0.0 · · · ·

All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row.

Minimum investment ₹10 lakh. SIF data from AMFI. Not investment advice. Verify all information with the fund house before investing.